Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novartis beats Q4 earnings consensus
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/103.DZznz2u5.js
Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
7h
Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries
Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...
3h
on MSN
Novartis has cash for a big pharma deal—but here’s why it’s not buying
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
7h
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
10h
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback